BOC-(R)-3-氨基-4-(3,4-二氟苯基)丁酸 | 269396-59-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - BOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: BOC-(R)-3-氨基-4-(3,4-二氟苯基)丁酸
• 中文别名: Boc-D-3-氨基-4-(3,4-二氟苯基)丁酸；(3R)-3-[(叔丁氧羰基)氨基]-4-(3,4-二氟苯基)丁酸；BOC-D-Β-3-氨基-4-(3,4-二氟苯基)-丁酸
• 英文名称: (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(3,4-difluorophenyl)butanoic acid
• 英文别名: (R)-3-(tert-butoxycarbonylamino)-4-(3,4-difluorophenyl)butanoic acid；3-(R)-t-butyloxycarbonylamino-4-(3,4-difluorophenyl)butyric acid；(R)-3-((tert-butoxycarbonyl)amino)-4-(3,4-difluorophenyl)butanoic acid；(3R)-4-(3,4-difluorophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• CAS: 269396-59-0
• 化学式: C₁₅H₁₉F₂NO₄
• mdl: MFCD01860952
• 分子量: 315.317
• InChiKey: XZGBRONJONQTTA-SNVBAGLBSA-N

物化性质

• 沸点：
  448.6±45.0 °C(Predicted)
• 密度：
  1.243

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.466
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  存储条件：2-8℃，请保持干燥。

反应信息

• 作为反应物：
  描述：

  BOC-(R)-3-氨基-4-(3,4-二氟苯基)丁酸 在 lithium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 (S)-1-[(R)-3-tert-Butoxycarbonylamino-4-(3,4-difluoro-phenyl)-butyryl]-pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  有效和选择性脯氨酸衍生的二肽基肽酶IV抑制剂。

  摘要：

  对Merck样品的内部筛选表明，脯氨酸衍生的高苯丙氨酸3作为DPP-IV抑制剂具有中等效力（DPP-IV IC50 = 1.9 microM）。对3的优化导致化合物37，它是迄今为止发现的最有效和选择性最强的DPP-IV抑制剂之一。

  DOI：

  10.1016/j.bmcl.2004.07.056
• 作为产物：
  描述：

  BOC-D-3,4-二氟苯丙氨酸 在 silver benzoate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 为溶剂， 反应 6.0h， 生成 BOC-(R)-3-氨基-4-(3,4-二氟苯基)丁酸
  参考文献：
  名称：

  发现有效的和选择性的基于β-高苯丙氨酸的二肽基肽酶IV抑制剂。

  摘要：

  内部筛选铅β-氨基酰基脯氨酸8的修饰得到了等价的噻唑烷化物9。对9的苯环的广泛SAR研究导致发现了一系列新的有效的和选择性的DP-IV抑制剂。事实证明，在2位上引入氟对于该系列的效能至关重要。2,5-二氟（22q）和2,4,5-三氟（22t）类似物是DP-IV的有效抑制剂（分别为IC（50）= 270、119nM）。

  DOI：

  10.1016/j.bmcl.2004.06.099

文献信息

• BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150359793A1

  公开（公告）日：2015-12-17

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物在治疗或预防二肽基肽酶-IV酶参与的疾病中具有用途，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：——

  公开号：US20040167133A1

  公开（公告）日：2004-08-26

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物对于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病非常有用。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物预防或治疗二肽基肽酶-IV酶参与的疾病的方法。
• NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
  申请人：Edmondson Scott D.

  公开号：US20110190308A1

  公开（公告）日：2011-08-04

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，这些化合物可用于治疗或预防涉及二肽基肽酶-IV酶的疾病，例如糖尿病，特别是2型糖尿病。本发明还涉及包括这些化合物的制药组合物以及在涉及二肽基肽酶-IV酶的这些疾病的预防或治疗中使用这些化合物和组合物。
• [EN] BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] PYRAZINES BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) ET PYRAZINES TETRAHYDROTRIOAZOLO (4, 3-A) UTILISEES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE DANS LE TRAITEMENT OU LA PREVENTION DU DIABETE
  申请人：MERCK & CO INC

  公开号：WO2003004498A1

  公开（公告）日：2003-01-16

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物可用于治疗或预防二肽基肽酶-IV酶参与的疾病，例如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶参与的这些疾病中使用这些化合物和组合物。
• Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：——

  公开号：US20030100563A1

  公开（公告）日：2003-05-29

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，这些化合物在治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，尤其是2型糖尿病方面具有用途。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶参与的这些疾病中使用这些化合物和组合物的用途。